Risk-Taking Behaviors in Huntington's Disease.


Journal

Journal of Huntington's disease
ISSN: 1879-6400
Titre abrégé: J Huntingtons Dis
Pays: Netherlands
ID NLM: 101589965

Informations de publication

Date de publication:
2020
Historique:
pubmed: 10 11 2020
medline: 9 11 2021
entrez: 9 11 2020
Statut: ppublish

Résumé

Risky behaviors are common in Huntington's disease (HD) and can lead to significant adverse consequences. However, the prevalence and scope of these symptoms have not been studied systematically, and no empirically validated measures are available to screen for them. To test a novel screening tool designed to assess risk-taking behaviors in HD. We administered the Risk Behavior Questionnaire (RBQ-HD) to HD patients and caregivers at Vanderbilt University Medical Center between 2018-2019. Patients completed the questionnaire based on self-report; caregivers provided collateral reports. Clinical and demographic information were obtained from the electronic medical record. 60 patients and 60 caregivers completed the RBQ-HD. 80% of patients (n = 48) and 91.7% of caregivers (n = 60) reported at least one risky behavior. Adverse social behaviors, impulsive/compulsive behaviors, and reckless driving were the most common behavioral domains reported. Male patients were more likely to report risky behaviors than females (92.3% vs. 70.6%, p = 0.04). The number of risky behaviors reported by patients and caregivers was negatively correlated with patient age (r = -0.32, p = 0.01; r = -0.47, p = 0.0001, respectively). Patient and caregiver reports were highly correlated in matched pairs (n = 30; r = 0.63, p = 0.0002). These findings emphasize that risky behaviors are highly prevalent in HD and can be effectively identified through the use of a novel screening measure. We hypothesize that early pathological involvement of frontostriatal and mesolimbic networks may be important factors in the development of these behaviors.

Sections du résumé

BACKGROUND
Risky behaviors are common in Huntington's disease (HD) and can lead to significant adverse consequences. However, the prevalence and scope of these symptoms have not been studied systematically, and no empirically validated measures are available to screen for them.
OBJECTIVE
To test a novel screening tool designed to assess risk-taking behaviors in HD.
METHODS
We administered the Risk Behavior Questionnaire (RBQ-HD) to HD patients and caregivers at Vanderbilt University Medical Center between 2018-2019. Patients completed the questionnaire based on self-report; caregivers provided collateral reports. Clinical and demographic information were obtained from the electronic medical record.
RESULTS
60 patients and 60 caregivers completed the RBQ-HD. 80% of patients (n = 48) and 91.7% of caregivers (n = 60) reported at least one risky behavior. Adverse social behaviors, impulsive/compulsive behaviors, and reckless driving were the most common behavioral domains reported. Male patients were more likely to report risky behaviors than females (92.3% vs. 70.6%, p = 0.04). The number of risky behaviors reported by patients and caregivers was negatively correlated with patient age (r = -0.32, p = 0.01; r = -0.47, p = 0.0001, respectively). Patient and caregiver reports were highly correlated in matched pairs (n = 30; r = 0.63, p = 0.0002).
CONCLUSION
These findings emphasize that risky behaviors are highly prevalent in HD and can be effectively identified through the use of a novel screening measure. We hypothesize that early pathological involvement of frontostriatal and mesolimbic networks may be important factors in the development of these behaviors.

Identifiants

pubmed: 33164940
pii: JHD200431
doi: 10.3233/JHD-200431
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

359-369

Auteurs

Katherine E McDonell (KE)

Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.

Abagail E Ciriegio (AE)

Department of Psychology and Human Development, Vanderbilt University, Nashville, TN, USA.

Anna C Pfalzer (AC)

Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.

Lisa Hale (L)

Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.

Shuhei Shiino (S)

Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.

Heather Riordan (H)

Department of Pediatrics, Division of Child Neurology, Vanderbilt Children's Hospital, United States.

Sarah Moroz (S)

Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.

R Ryan Darby (RR)

Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.

Bruce E Compas (BE)

Department of Psychology and Human Development, Vanderbilt University, Nashville, TN, USA.

Daniel O Claassen (DO)

Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH